4.7 Article

Aneurysmal Subarachnoid Hemorrhage in Hospitalized Patients on Anticoagulants-A Two Center Matched Case-Control Study

Related references

Note: Only part of the references are listed.
Review Medicine, General & Internal

Spontaneous subarachnoid haemorrhage

Jan Claassen et al.

Summary: Subarachnoid hemorrhage (SAH) is the third most common subtype of stroke. The incidence has decreased over the years, possibly due to lifestyle changes. A quarter of SAH patients die before hospital admission, and those admitted to the hospital have improved outcomes but may experience long-term neuropsychiatric complications. Severe sudden headache is the most common symptom, and diagnosis is typically made through CT scan and angiography. Treatment focuses on reducing the risk of rebleeding and early aneurysm treatment.

LANCET (2022)

Article Critical Care Medicine

Revisiting the Timeline of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: Toward a Temporal Risk Profile

Tobias Philip Schmidt et al.

Summary: This study assessed the temporal risk profile of delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (SAH) and found that early occurrence of DCI is associated with a higher infarct load and DCI-related mortality.

NEUROCRITICAL CARE (2022)

Article Clinical Neurology

Invasive neuromonitoring with an extended definition of delayed cerebral ischemia is associated with improved outcome after poor-grade subarachnoid hemorrhage

Michael Veldeman et al.

Summary: The introduction of invasive neuromonitoring in poor-grade SAH patients allowed for earlier detection of delayed cerebral ischemia events, resulting in a significant decrease in infarction rates and an improvement in patient outcomes.

JOURNAL OF NEUROSURGERY (2021)

Article Hematology

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

Jack Ansell et al.

Summary: Ciraparantag is a small molecule designed to reverse the effects of anticoagulants, showing rapid onset and short half-life. It has the potential to reduce blood loss in animal models and serve as a DOAC reversal agent.

BLOOD (2021)

Article Clinical Neurology

Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral Infarction

Matthew J. Kole et al.

Summary: This study compared the effects of LDIVH and SQH on the in-hospital outcomes of aSAH patients. The LDIVH group had a lower rate of cerebral infarction, with patients less likely to experience DND and cerebral infarction compared to the SQH group. However, there were no significant differences between the two groups in terms of hemorrhagic complications, heparin-induced thrombocytopenia, and DVT.

NEUROSURGERY (2021)

Article Cardiac & Cardiovascular Systems

Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting

Saima Afzal et al.

Summary: Prescribing patterns and costs of direct-acting oral anticoagulants (DOACs) in primary care in England have been increasing annually, with a decrease in reporting of serious and fatal events. Regional differences in anticoagulant prescribing may be influenced by changes in national guidelines and population increases. DOACs are making a growing contribution to total anticoagulant prescription items and costs.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Article Hematology

Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry

Jean-Pierre Bassand et al.

Summary: In patients with atrial fibrillation, NOACs show lower risks of bleeding and all-cause mortality compared to VKAs, with major bleeding associated with the highest risk of death. Minor bleeding and CRNM bleeding are also linked to a higher risk of death compared to no bleeding. A significant percentage of deaths within 30 days after a major bleed are due to intracranial/intraspinal hemorrhage.

BLOOD ADVANCES (2021)

Editorial Material Endocrinology & Metabolism

Acute micro-thrombosis after subarachnoid hemorrhage: A new therapeutic target?

Fenghui Ye et al.

Summary: Microthrombi formation in the brain following SAH has been linked to cerebral ischemia, with a recent study showing ultra-early micro-thrombosis occurring four hours post-SAH. The number of thrombotic microvessels was found to correlate with brain-blood barrier disruption and neuronal injury, prompting consideration for thrombolytic therapy development for SAH patients.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2021)

Article Clinical Neurology

One-Year Outcome After Aneurysmal Subarachnoid Hemorrhage in Elderly Patients

Jyri J. Virta et al.

WORLD NEUROSURGERY (2020)

Review Hematology

Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum

Adam Cuker et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Review Hematology

Integrating platelet and coagulation activation in fibrin clot formation

Frauke Swieringa et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)

Article Cardiac & Cardiovascular Systems

Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation

Andreas Zirlik et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)

Article Medicine, General & Internal

Subarachnoid Hemorrhage

Michael T. Lawton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Clinical Neurology

Novel Oral Anticoagulants in Patients Undergoing Cranial Surgery

Davide Marco Croci et al.

WORLD NEUROSURGERY (2017)

Article Medicine, General & Internal

Idarucizumab for Dabigatran Reversal

Charles V. Pollack et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Deborah M. Siegal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Multidisciplinary Sciences

Risk Factors for Rebleeding of Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis

Chao Tang et al.

PLOS ONE (2014)

Article Neuroimaging

The safety of anticoagulation in patients with intracranial aneurysms

Nicholas Tarlov et al.

JOURNAL OF NEUROINTERVENTIONAL SURGERY (2013)

Article Medicine, General & Internal

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Robert P. Giugliano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Hematology

Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage

R. Risselada et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)

Article Medicine, General & Internal

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Use of vitamin K antagonists and risk of subarachnoid haemorrhage: A population-based case-control study

Morten Olsen et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2010)

Article Medicine, General & Internal

Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

Stuart J. Connolly et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Clinical Neurology

The increasing incidence of anticoagulant-associated intracerebral hemorrhage

M. L. Flaherty et al.

NEUROLOGY (2007)

Article Clinical Neurology

Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage

AM Naidech et al.

ARCHIVES OF NEUROLOGY (2005)

Review Critical Care Medicine

Subarachnoid hemorrhage grading scales - A systematic review

DS Rosen et al.

NEUROCRITICAL CARE (2005)

Article Critical Care Medicine

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

MM Levy et al.

CRITICAL CARE MEDICINE (2003)